FDA approves ‘osteoporosis’ tablet
Freienbach, March 15, 2012
EffRx Pharmaceuticals has announced that US Food and Drug Administration (FDA) has approved Binosto (alendronate sodium) Effervescent Tablets, previously known as EX101.
The tablets are used for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis.
EffRx anticipates that Binosto will be commercially available in the United States in the third quarter of 2012.
Christer Rosén, chairman and CEO of EffRx, said: “Binosto is a breakthrough innovation for the treatment of osteoporosis, offering those patients that have difficulty with tablets the proven fracture risk reduction of alendronate in a pleasant tasting and easy to swallow buffered solution.”
Osteoporosis affects more than 200 million people in the 7 major markets and the global market is estimated to be $10 billion and growing, especially in the emerging markets.
Binosto is an innovative treatment option that can assure physicians that they are providing a proven efficacious therapy for those patients who have difficulty with tablets.
A Harris Interactive Poll concluded that up to 40 per cent of American adults have difficulties with swallowing tablets. – TradeArabia News Service
More Health & Environment Stories
- Mackeen unveils document management solution
- Seha opens new clinics in Abu Dhabi, Al Ain
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman
- Al Noor Hospitals targets domestic growth
- Medical panel on the way in Bahrain
- 40pc of UAE adults ‘have hypertension’
- Saudi diabetics urged to stay away from camels
- GCC readies plan to fight heart diseases
- Bahrain opens sickle cell hospital
- Hazardous waste focus for Oman summit
- Infectious viruses to be tracked by satellite in UAE
- Mafraq Hospital names new surgery chief
- Saudi health ministry seals BMJ partnership
- Need for medical simulation training highlighted
- UAE-France discuss healthcare collaboration
- Seha focus on patient centred services